Detalhe da pesquisa
1.
Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence.
Am J Pathol
; 193(1): 51-59, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243045
2.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722621
3.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood
; 138(21): 2042-2050, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407543
4.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
5.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood
; 136(6): 674-683, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285126
6.
Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population.
J Thromb Thrombolysis
; 46(4): 483-487, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30191357
7.
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Clin Transl Sci
; 17(3): e13742, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38494922
8.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.
Blood Adv
; 8(6): 1515-1528, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290135
9.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
; 11(1): e15-e26, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135371
10.
The RNA Modification Database, RNAMDB: 2011 update.
Nucleic Acids Res
; 39(Database issue): D195-201, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21071406
11.
Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors.
Heliyon
; 9(5): e16261, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37251903
12.
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Blood Adv
; 7(24): 7494-7500, 2023 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903324
13.
The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Breast Cancer Res Treat
; 131(2): 699-708, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22076476
14.
Measurable Residual Disease in High-Risk Acute Myeloid Leukemia.
Cancers (Basel)
; 14(5)2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267586
15.
Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study.
Cancer Med
; 11(5): 1292-1298, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35106962
16.
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms.
Front Oncol
; 12: 923809, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35774119
17.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
J Clin Oncol
; 40(35): 4048-4059, 2022 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35849791
18.
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia.
Blood Adv
; 4(3): 449-457, 2020 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32012214
19.
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment.
Clin Adv Hematol Oncol
; 11(3): 184-8, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23598988
20.
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.
Clin Cancer Res
; 24(10): 2294-2303, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29463550